p53 but not bcl-2 is expressed by most cholangiocarcinomas: a study of 28 cases

被引:26
作者
Arora, DS
Ramsdale, J
Lodge, JPA
Wyatt, JI
机构
[1] St James Univ Hosp, Dept Histopathol, Leeds LS7 9TF, W Yorkshire, England
[2] St James Univ Hosp, Dept Hepatobiliary Surg, Leeds LS7 9TF, W Yorkshire, England
关键词
bcl-2; bile duct; cholangiocarcinoma; p53; prognosis; surgery;
D O I
10.1111/j.1365-2559.1999.00654.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Aims: To examine the frequency and pattern of expression of p53 and bcl-2 in archival material from patients with cholangiocarcinomas and to evaluate their respective roles in its pathogenesis, diagnosis and prognosis. Methods and results: Twenty-eight surgical cases of cholangiocarcinomas diagnosed at St James's University Hospital and 16 control cases were immunostained with monoclonal antibodies to p53 and bcl-2 using streptavidin-biotin complex method. Pressure cooker was used for antigen retrieval, Of the cholangiocarcinomas, 85.7% (24/28) overexpressed p53. The intensity of staining in these cases varied from If in 2, 2+ in 10 and 3+ in 12 cases. None of the 28 tumours expressed bcl-2. The well differentiated nature of the tumour made assessment of dysplasia difficult, however, where present it did not express p53 or bcl-2, The bile duct epithelium adjacent to the tumour and in the control cases did not show any significant nuclear staining for either antigen. Conclusions: Overexpression of p53 appears to play an important role as a late event in the pathogenesis of cholangiocarcinomas, while we found no evidence of bcl-2 overexpression. The expression of p53 in 86% of the invasive tumours, as compared to its lack in the adjacent normal bile duct epithelium, makes it potentially useful in the diagnostic histopathology of these cases.
引用
收藏
页码:497 / 501
页数:5
相关论文
共 21 条
  • [1] Dergham ST, 1997, CANCER, V80, P372, DOI 10.1002/(SICI)1097-0142(19970801)80:3<372::AID-CNCR4>3.0.CO
  • [2] 2-U
  • [3] FREDERIC C, 1994, AM J PATHOL, V144, P460
  • [4] LOCALIZATION OF GENE FOR HUMAN P53 TUMOR-ANTIGEN TO BAND 17P13
    ISOBE, M
    EMANUEL, BS
    GIVOL, D
    OREN, M
    CROCE, CM
    [J]. NATURE, 1986, 320 (6057) : 84 - 85
  • [5] MUTATIONS OF THE P53 TUMOR-SUPPRESSOR GENE AND THE RAS GENE FAMILY IN INTRAHEPATIC CHOLANGIOCELLULAR CARCINOMAS IN JAPAN AND THAILAND
    KIBA, T
    TSUDA, H
    PAIROJKUL, C
    INOUE, S
    SUGIMURA, T
    HIROHASHI, S
    [J]. MOLECULAR CARCINOGENESIS, 1993, 8 (04) : 312 - 318
  • [6] THE P53 TUMOR-SUPPRESSOR GENE
    LEVINE, AJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (20) : 1350 - 1352
  • [7] Manne U, 1997, INT J CANCER, V74, P346, DOI 10.1002/(SICI)1097-0215(19970620)74:3<346::AID-IJC19>3.0.CO
  • [8] 2-9
  • [9] Muller W, 1996, J PATHOL, V178, P255, DOI 10.1002/(SICI)1096-9896(199603)178:3<255::AID-PATH468>3.0.CO
  • [10] 2-V